Abstract
Despite improved hepatitis C virus (HCV) treatments, vaccines remain an effective and economic option for curtailing the epidemic. Mosaic protein HCV genotype 1 vaccine candidates designed to address HCV diversity were immunogenic in mice. They elicited stronger T-cell responses to NS3-NS4a and E1-E2 proteins than did natural strains, as assessed with vaccine-matched peptides.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Viral / immunology
-
Hepacivirus / genetics
-
Hepacivirus / immunology*
-
Hepatitis C / immunology*
-
Hepatitis C / prevention & control
-
Mice
-
Mice, Inbred BALB C
-
T-Lymphocytes / immunology*
-
Vaccination
-
Vaccines, Synthetic
-
Viral Envelope Proteins / immunology
-
Viral Hepatitis Vaccines / administration & dosage
-
Viral Hepatitis Vaccines / genetics
-
Viral Hepatitis Vaccines / immunology*
-
Viral Nonstructural Proteins / immunology
Substances
-
Antibodies, Viral
-
E1 protein, Hepatitis C virus
-
NS3 protein, hepatitis C virus
-
Vaccines, Synthetic
-
Viral Envelope Proteins
-
Viral Hepatitis Vaccines
-
Viral Nonstructural Proteins